Interestingly, stocks in both the anti-cancer
biotech and medical #$%$ segments are
trading smack dab in the middle of their 52-week
ranges. This will likely change in the coming weeks
heading into the annual American Society of Clinical
Oncology (ASCO) meeting in early June. Anti-cancer
stocks tend to move sharply higher in the weeks prior
to the conference.